The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer

Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences